Cargando…

Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review

INTRODUCTION: Although dual antiplatelet therapy (DAPT) is routinely given to patients after percutaneous coronary intervention (PCI) with stenting, the optimal duration is unknown. Recent evidence indicates there may be benefits in extending the duration beyond 12 months but such decisions may incr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elliott, Jesse, Kelly, Shannon E, Bai, Zemin, Liu, Wenfei, Skidmore, Becky, Boucher, Michel, So, Derek Y F, Wells, George A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387937/ https://www.ncbi.nlm.nih.gov/pubmed/28377396 http://dx.doi.org/10.1136/bmjopen-2016-015421

Ejemplares similares

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
por: Elliott, Jesse, et al.
Publicado: (2019)

Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis
por: Elliott, Jesse, et al.
Publicado: (2023)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

Duration of Dual Antiplatelet Therapy After Implantation of Drug-Coated Balloon
por: Zhang, Yuxuan, et al.
Publicado: (2021)

Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
por: Farag, Mohamed, et al.
Publicado: (2022)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

Duration and clinical outcomes of dual antiplatelet therapy following percutaneous coronary intervention for acute coronary syndrome: A multicentre “real-world practice” registry-based study
por: Vergara-Uzcategui, Carlos E., et al.
Publicado: (2023)

Oral antiplatelet therapy in the elderly undergoing percutaneous coronary intervention: an umbrella review
por: Biondi-Zoccai, Giuseppe, et al.
Publicado: (2020)

Shortening Dual Antiplatelet Therapy Duration in High-Risk Patients Undergoing Percutaneous Coronary Intervention
por: Greco, Antonio, et al.
Publicado: (2023)

Duration of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Treated With New Generation Stents: A Meta-Analysis of Randomized Controlled Trials
por: Zhang, Wen-Jiao, et al.
Publicado: (2021)

Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014–2019)
por: Mezier, A., et al.
Publicado: (2023)

Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations
por: Cui, Kongyong, et al.
Publicado: (2021)

Incorporation of Laboratory Test Biomarkers Into Dual Antiplatelet Therapy Score Improves Prediction of Ischemic and Bleeding Events in Post-percutaneous Coronary Intervention Patients
por: Sun, Chengming, et al.
Publicado: (2022)

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)

Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion
por: Lee, Seung Hwa, et al.
Publicado: (2017)

Extended Duration of Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?
por: Howard, Charles E., et al.
Publicado: (2019)

Duration of dual antiplatelet therapy in acute coronary syndrome
por: Wilson, Simon John, et al.
Publicado: (2017)

Dual Antiplatelet Therapy vs. Single Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: An Updated Systematic Review and Meta-Analysis
por: Zhang, Yipeng, et al.
Publicado: (2021)

Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent
por: Huseynov, Aydin, et al.
Publicado: (2019)

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis
por: Elliott, Jesse, et al.
Publicado: (2020)

Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy
por: Karanasos, Antonios, et al.
Publicado: (2014)

Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis
por: Elliott, Jesse, et al.
Publicado: (2017)

Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain)
por: Ribera, Aida, et al.
Publicado: (2019)

Prolonged dual antiplatelet therapy for Chinese ACS patients undergoing emergency PCI with drug-eluting stents: Benefits and risks
por: Zhang, Yong, et al.
Publicado: (2023)

Optimal duration of dual antiplatelet therapy for coronary artery disease
por: Kikkert, W. J., et al.
Publicado: (2018)

A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making
por: Johnston, Amy, et al.
Publicado: (2018)

Effectiveness and Safety of Antibiotic Prophylaxis for Persons Exposed to Cases of Invasive Group A Streptococcal Disease: A Systematic Review
por: Khan, Faizan, et al.
Publicado: (2022)

Dual Loading Antiplatelet Therapy in Patients With Acute Coronary Syndrome and High Bleeding Risk Undergoing Percutaneous Coronary Intervention: Findings From the Improving Care for Cardiovascular Disease in China Project
por: Yan, Yan, et al.
Publicado: (2022)

P2y(12) inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
por: Yu, Yanqiao, et al.
Publicado: (2023)

Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review
por: Oliva, Angelo, et al.
Publicado: (2023)

Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial?
por: Jhang, Kai-Ming, et al.
Publicado: (2015)

Extended Duration Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Peripheral Arterial Disease: A Meta-Analysis
por: Ling, Hua, et al.
Publicado: (2018)

Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis
por: Yin, Shang-He-Lin, et al.
Publicado: (2019)

Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction
por: Yeh, Jong-Shiuan, et al.
Publicado: (2023)

Case report: Reducing the duration of positive-pressure ventilation for large mediastinal masses
por: Zhang, Zaili, et al.
Publicado: (2022)

Safety of Percutaneous Dilatational Tracheotomy in Patients on Dual Antiplatelet Therapy and Anticoagulation
por: Lüsebrink, Enzo, et al.
Publicado: (2019)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis
por: Kwok, Chun Shing, et al.
Publicado: (2014)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
por: Navarese, Eliano Pio, et al.
Publicado: (2015)

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0e00tatmi04cig3ravkrac6tpq